FIELD: medicine, phthisiology, pharmacy. SUBSTANCE: invention proposes to use taufon as a tuberculostatic agent. EFFECT: expanded assortment of agents of indicated designation. 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
TUBERCULOSTAT AGENT | 2001 |
|
RU2185170C1 |
METHOD OF TREATMENT OF EXPERIMENTAL TUBERCULOSIS | 2001 |
|
RU2207127C1 |
TUBERCULOSTATIC AGENT | 1998 |
|
RU2153339C1 |
ANTI-TUBERCULOSIS PREPARATION | 2002 |
|
RU2211035C1 |
METHOD FOR TREATING THE CASES OF TUBERCULOSIS | 2002 |
|
RU2212240C1 |
METHOD FOR TREATING THE CASES OF EXPERIMENTAL TUBERCULOSIS | 2000 |
|
RU2165761C1 |
5-FLUORO-2-(4-ETHOXYCARBONYLDIPIPERAZINE-1-YL)-1,3-BENZOTHIAZINE-4-ONE, WHICH HAS ANTI-TUBERCULOSIS ACTIVITY | 2018 |
|
RU2663848C1 |
METHOD FOR DETERMINATION OF EFFICIENCY OF DISINFECTANTS USED IN TB FACILITIES | 2008 |
|
RU2364629C1 |
N-(2-AMINOPURIN-6-YL)GLYCYL-(S)-GLUTAMIC ACID, HAVING ANTI-TUBERCULOSIS ACTIVITY | 2015 |
|
RU2604068C1 |
N-(2-ACETAMIDOPURIN-6-YL)GLYCINE, WHICH HAS ANTI-TUBERCULOSIS ACTIVITY | 2014 |
|
RU2570113C1 |
Authors
Dates
2003-06-27—Published
2002-03-18—Filed